Clinical Trial Results

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

The once-weekly amylin analog also improved cardiometabolic markers with fewer side effects on slower dose escalation.